Q1 FY2026 Performance Highlights
- Revenue at ₹11,197m, grew 6.2% YoY
- Absolute gross margin at ₹6,755m, grew 11.7% YoY
- Gross margin improved to 60.3%, up 300bps YoY
- EBITDA grew 14.8% YoY to ₹2,181m with EBITDA margin at 19.5%, grew 150bps YoY
- US revenue at $71m, grew 7.0% YoY
- Operational PAT at ₹1,140m, Grew 80.6% YoY
- Operational EPS at ₹12.4
- Reported PAT at ₹1,056m
Bangalore, India : Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q1FY26) ended June 30, 2025.
Financial Highlights (In ₹ m)
| Particulars | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
| Revenue | 11,197 | 10,543 | 6.2% | 11,904 | -5.9% |
| Gross Margin | 6,755 | 6,045 | 11.7% | 6,914 | -2.3% |
| Gross Margin % | 60.3% | 57.3% | 300bps | 58.1% | 220bps |
| EBITDA | 2,181 | 1,900 | 14.8% | 2,179 | 0.1% |
| EBITDA % | 19.5% | 18.0% | 150bps | 18.3% | 120bps |
| Operational PAT* | 1,140 | 631 | 80.6% | 1,130 | 0.8% |
| Operational EPS (₹) | 12.4 | 6.9 | 12.3 |
*Operational PAT = Reported PAT from continuing operations excluding exceptional items
Q1FY25 Numbers presented reflect the restated financials post the demerger of Softgel business
Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5%, an increase of 150bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of ₹12.4. Consequently, ROCE stands at 15.1% for Q1. The company will enhance its R&D efforts during the year to drive sustainable long-term growth.”
Leave a Reply